OrthoPediatrics (KIDS) Reports Q4 Loss, Misses Revenue Estimates

Core Viewpoint - OrthoPediatrics reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.22, marking an earnings surprise of -31.82% [1] Financial Performance - The company posted revenues of $52.67 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.06$37.61 million in the same quarter last year [2] - Over the last four quarters, OrthoPediatrics has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - OrthoPediatrics shares have lost about 0.1% since the beginning of the year, compared to a decline of -0.5% for the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of$52.47 million, and for the current fiscal year, it is -$0.86 on revenues of$239.3 million [7] - The trend of estimate revisions for OrthoPediatrics is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Instruments industry, to which OrthoPediatrics belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]